First AD

Second AD

Shubham Pant, MD, MBBS, is a professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center 

Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

Video content above is prompted by the following:

We have several currently available therapies for those with HER2-amplified and HER2-positive tumors. What are your main takeaways from the DESTINY-PanTumor 02 trial with trastuzumab deruxtecan?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Exploring Biliary Tract Cancer: Top Takeaways From ASCO GI 2025 

Peer Exchange

Panelists discuss how the DESTINY-PanTumor 02 trial demonstrated significant efficacy of trastuzumab deruxtecan in HER2-amplified biliary tract cancer (BTC), with promising response rates and durability that support its use as a treatment option for these patients.